Perimidine (including Hydrogenated) Patents (Class 514/268)
-
Publication number: 20140309185Abstract: This document relates to inhibitors of G protein coupled receptor 6 kinase (GRK6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.Type: ApplicationFiled: October 26, 2012Publication date: October 16, 2014Inventors: Alexander Keith Stewart, Artem Plekhov, Robert Greenhouse
-
Patent number: 8835447Abstract: Provided is a method of inhibiting growth of androgen receptor positive cancer cells. The method entails administering to an individual diagnosed with or suspected of having an androgen receptor positive cancer and administering to the individual a composition containing a compound that can inhibit the growth of the androgen receptor positive cancer.Type: GrantFiled: October 25, 2010Date of Patent: September 16, 2014Assignees: Health Research Inc., Panacela Labs, Inc.Inventors: Katerina Gurova, Natalya Narizhneva
-
Patent number: 8623886Abstract: Pharmaceutical compositions for interfering with neuronal transmission comprising an effective amount of at least one tricyclic 3,4-propinoperhydropurine and at least one additional compound are disclosed. Preparations for topical applications are provided that comprise an effective amount of the composition of the invention and a pharmacologically acceptable carrier. Methods of interfering with neuronal transmission comprising topical application of an effective amount of the at least one tricyclic 3,4-propinoperhydropurine are provided for treatment of a variety of indications that relate to muscle relaxation, anesthesia, muscle spasms and similar causes.Type: GrantFiled: June 19, 2012Date of Patent: January 7, 2014Assignee: Phytotox LimitedInventor: Nestor Antonio Lagos Wilson
-
Patent number: 8614221Abstract: The instant invention provides for substituted fused naphthyridine derivatives that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.Type: GrantFiled: March 10, 2010Date of Patent: December 24, 2013Assignees: Merck Sharp & Dohme Corp., MSD K.K.Inventors: Weiming Fan, Thomas F. N. Haxell, Matthew G. Jenks, Nobuhiko Kawanishi, Shuliang Lee, Hao Liu, Michael J. Malaska, Joseph A. Moore, III, Yoshio Ogino, Yu Onozaki, Bharathi Pandi, Michael R. Peel, Toshihiro Sakamoto, Tony Siu
-
Patent number: 8450334Abstract: Compositions and methods are provided for preventing or attenuating cancer progression or blocking metastasis in prostate cancer and other cancers (e.g., ovarian carcinoma, endometrial cancer, renal cell carcinoma) that are characterized by overexpression of the type II cell surface serine protease hepsin, based on the discovery of multiple disclosed compounds having activity as specific hepsin inhibitors.Type: GrantFiled: May 21, 2009Date of Patent: May 28, 2013Assignee: Fred Hutchinson Cancer Research CenterInventors: Valeri I. Vasioukhin, John R. Chevillet
-
Publication number: 20120264771Abstract: Provided is a method of inhibiting growth of androgen receptor positive cancer cells. The method entails administering to an individual diagnosed with or suspected of having an androgen receptor positive cancer and administering to the individual a composition containing a compound that can inhibit the growth of the androgen receptor positive cancer.Type: ApplicationFiled: October 25, 2010Publication date: October 18, 2012Applicants: PANACELA LABS, INC., HEALTH RESEARCH INC.Inventors: Katerina Gurova, Natalya Narizhneva
-
Publication number: 20110144139Abstract: Compositions and methods are provided for preventing or attenuating cancer progression or blocking metastasis in prostate cancer and other cancers (e.g., ovarian carcinoma, endometrial cancer, renal cell carcinoma) that are characterized by overexpression of the type II cell surface serine protease hepsin, based on the discovery of multiple disclosed compounds having activity as specific hepsin inhibitors.Type: ApplicationFiled: May 21, 2009Publication date: June 16, 2011Inventors: Valeri I. Vasioukhin, John R. Chevillet
-
Publication number: 20100297046Abstract: The invention relates to compounds and methods for inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin, by way of fructosamine-3-kinase inhibition, thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS and AGEs, which are associated with the inflammatory response caused by oxidative stress.Type: ApplicationFiled: March 30, 2007Publication date: November 25, 2010Applicant: DYNAMIS THERAPEUTICS, INC.Inventors: Michael Schwartz, Francis Kappler, Bangying Su
-
Publication number: 20100267753Abstract: The invention provides methods for the treatment or amelioration of disorders associated with undesired activity of protein kinase CK2, using compounds of Formula (I) that are potent, selective inhibitors of CK2, and pharmaceutical compositions of such compounds, wherein Z5, R6B, R6D, R8, n, R9 and p are defined as further described herein,Type: ApplicationFiled: April 16, 2010Publication date: October 21, 2010Inventors: Mustapha HADDACH, Sean O'Brien, Kenna Anderes
-
Patent number: 7601723Abstract: The present invention provides compounds and pharmaceutical compositions that are substituted pyridyl-linked-xanthines of formula I which are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.Type: GrantFiled: February 27, 2006Date of Patent: October 13, 2009Assignee: PGx Health, LLCInventors: Guoquan Wang, Jayson M. Rieger, Robert D. Thompson
-
Publication number: 20090117040Abstract: The present invention relates to pharmaceutical and diagnostic compositions as well as to the use of the active substances contained therein for preparing a pharmaceutical or a diagnostic composition for the treatment or diagnosis of neurodegenerative disorders or amyloid diseases.Type: ApplicationFiled: February 11, 2005Publication date: May 7, 2009Applicant: Max-Delbrug-Centrum Fur Molekulare MedizinInventors: Erich Wanker, Sabine Engemann, Susanne Rautenberg, Annett Boeddrich, Phoebe Markovic, Dagmar Ehrnhofer, Martin Herbst, Jacqueline Walther
-
Publication number: 20090074791Abstract: The present invention relates to substituted phenylisoquinoline and phenylquinazoline derivatives and to their pharmaceutical uses in preventing or treating bone conditions which are associated with increased calcium depletion or resorption or in which stimulation of bone formation and calcium fixation in the bone is desirable.Type: ApplicationFiled: September 2, 2008Publication date: March 19, 2009Inventor: Rene Beerli
-
Patent number: 7126001Abstract: The present invention provides the compound having the formula: wherein each of R1 and R2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, t-butyl, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, —O—, —S—, —NH—, or —CH2—; and wherein n is an integer from 3 to 8. The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above.Type: GrantFiled: October 25, 2002Date of Patent: October 24, 2006Assignees: Sloan-Kettering Institute for Cancer Research, The Trustees of Columbia University in the City of New YorkInventors: Ronald Breslow, Sandro Belvedere, Leland Gershell, Thomas A. Miller, Paul A. Marks, Victoria M. Richon, Richard A. Rifkind
-
Publication number: 20020049206Abstract: The treatment of addictive disorders, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction, and nicotine addiction using a heterocyclic amine, a phenylazacycloalkane, a cabergoline, or an aromatic bicyclic amine active agent, or a pharmaceutically acceptable derivative or salt of any said active agent is described herein.Type: ApplicationFiled: August 14, 2001Publication date: April 25, 2002Inventors: Richard W. Anderson, Sylvia S. McBrinn, David W. Robertson, Robert C. Marshall
-
Patent number: 6169105Abstract: The power of citalopram, fluvoxamine and paroxetine to increase the availability of sarotonin, norepinephrine and dopamine, particularly serotonin, is augmented by administration in combination with a drug which is a serotonin 1A receptor antagonist.Type: GrantFiled: November 25, 1996Date of Patent: January 2, 2001Assignee: Eli Lilly and CompanyInventors: David Taiwai Wong, Juan Ignacio Oguiza
-
Patent number: 5395610Abstract: Potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are dibenz[b,e]oxepins such as doxepin.Type: GrantFiled: May 28, 1993Date of Patent: March 7, 1995Assignee: Burroughs-Wellcome Co.Inventor: Ann C. King
-
Patent number: 5300282Abstract: Potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are dibenz[b,e]oxepins such as doxepin.Type: GrantFiled: June 18, 1990Date of Patent: April 5, 1994Assignee: Burroughs-Wellcome CompanyInventor: Ann C. King
-
Patent number: 4800204Abstract: The control of tobacco use in humans with a direct dopamine receptor agonist.Type: GrantFiled: May 5, 1988Date of Patent: January 24, 1989Inventor: Peter S. Mueller
-
Patent number: 4625026Abstract: In one aspect, compounds having antiviral activity and having the general formula: ##STR1## wherein each R.sup.2, independently, is H or lower (fewer than 6 carbon atoms) alkyl; each R.sup.3, independently, is H or lower alkyl R.sup.0 is H or lower alkyl, R.sup.1 is H or lower alkyl; 1.ltoreq.n.ltoreq.11; n-2.ltoreq.m.ltoreq.2n; 0.ltoreq.p.ltoreq.3; z is 0 or 1; and p.ltoreq.q.ltoreq.2p; each n, m, p and q being selected so that the sp.sup.3 valence shell of each carbon atom in each ring is filled; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 13, 1983Date of Patent: November 25, 1986Assignee: Biomeasure, Inc.Inventor: Sun H. Kim